Promoters of Themis Medicare Limited and its subsidiary Gujarat Themis Biosyn Limited released pledged shares totaling 56,95,000 equity shares in July 2026. The releases were driven by the repayment of loans, significantly reducing the encumbrance on the promoter group's shareholding. Disclosures were submitted to BSE Limited and National Stock Exchange of India Limited on July 16 and July 20, 2026, in compliance with Regulation 31 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Release of Pledges by Themis Medicare Promoter

Vividhmargi Investments Private Limited, a promoter of Themis Medicare Limited, released pledges over 15,00,000 equity shares on July 8, 2026. The release was executed in favour of Bajaj Finance Limited. Prior to this transaction, the entity held encumbered shares representing 1.63% of the total share capital. Following the release, the remaining encumbered holding stands at NIL.

Release of Pledges by Gujarat Themis Biosyn Promoters

Promoter group entities of Gujarat Themis Biosyn Limited, Themis Medicare Limited and Pharmaceutical Business Group (India) Limited, released pledges over 41,95,000 equity shares on July 8, 2026. The release was executed in favour of Jio Credit Limited and Bajaj Finance Limited. Prior to these transactions, the promoter group held encumbered shares representing 3.85% of the total share capital. Following the release, the remaining encumbered holding stands at 5,000 shares, which constitutes 0.004% of the total equity share capital.

Shareholding and Encumbrance Status

The tables below detail the promoters' shareholding and the status of the encumbrance post the release events:

Promoter Sachin D. Patel has disclosed an intention to acquire up to 5,25,000 equity shares of Gujarat Themis Biosyn Limited from Pharmaceutical Business Group (India) Limited. The proposed acquisition, valued at up to ₹20 Crores, will take place between July 21, 2026, and July 31, 2026, at a price of ₹382 per equity share. This inter-se transfer among the promoter group will increase Patel's stake to 2.77% from the current 2.29%, while the seller's holding will reduce to 46.54% from 47.02%.

The transaction is being conducted under Regulation 10(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The acquisition is exempt from the requirement to make an open offer under Regulation 10(1)(a)(ii). The price of ₹382 per share is within the permissible limit, not exceeding 25% of the volume weighted average market price of ₹380.37 per equity share calculated over the 60 trading days preceding the notice.

Sachin D. Patel confirmed that both the transferor and transferee have complied with applicable disclosure requirements in Chapter V of the SEBI (SAST) Regulations, 2011, during the three years prior to the proposed acquisition. The acquirer also declared that all conditions specified under Regulation 10(1)(a)(ii) regarding exemptions have been duly complied with.

A previous disclosure made on July 1, 2026, regarding the same transaction was disregarded as it could not be acted upon within the stipulated period. The new disclosure supersedes the earlier intimation. The actual number of shares acquired may be less than the proposed 5,25,000 equity shares.

Shareholding Details

Transaction Key Points

• Acquirer: Sachin D. Patel (Promoter)
• Target: Gujarat Themis Biosyn Limited
• Seller: Pharmaceutical Business Group (India) Limited
• Shares: Up to 5,25,000 equity shares (0.50%)
• Price: ₹382 per equity share
• Period: July 21, 2026 to July 31, 2026